|
Abstract: . . . OPTISTIM was designed as a prospective, monocentre, double-blind and placebo-controlled randomized pilot- trial. It is the first placebo-controlled clinical trial for the investigation of SCS in RAP. Methods: Patients (n=12) had to be implanted with an SCS-Device for at least 3 months and were . . . . . . as a prospective, monocentre, double-blind and placebo-controlled randomized pilot- trial. It is the first placebo-controlled clinical trial for the investigation of SCS in RAP. Methods: Patients (n=12) had to be implanted with an SCS-Device for at least 3 months and were already defined as . . . --642,2,160,801,3211
|